Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.42 |
| ▸ | NPY4R | P50391 | 10/20 | 0.41 |
| ▸ | NPY5R | Q15761 | 9/20 | 0.41 |
| ▸ | NPY1R | P25929 | 8/20 | 0.41 |
| ▸ | NPY2R | P49146 | 6/20 | 0.41 |
| ▸ | FURIN | P09958 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | REN | P00797 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22336351 | 0.93 | TRPV1 (0.44) | TRPV1NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL22336348 | 0.93 | TRPV1 (0.44) | TRPV1NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL23815045 | 0.92 | CHRND (0.44) | TRPV1NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL24496495 | 0.91 | TRPV1 (0.45) | TRPV1NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL24029087 | 0.90 | TRPV1 (0.43) | TRPV1NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL22702533 | 0.90 | NPY5R (0.47) | TRPV1NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL21754508 | 0.89 | NPY4R (0.47) | TRPV1NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL25826708 | 0.89 | NPY4R (0.47) | TRPV1NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL24496677 | 0.88 | TRPV1 (0.43) | TRPV1NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL27432789 | 0.87 | NPY4R (0.44) | TRPV1NPY4RNPY5RNPY1RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200376135-A1 | FC SILENCED ANTIBODY DRUG CONJUGATES (ADCS) AND USES THEREOF | Magenta Therapeutics, Inc. (US) | 2020-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200376135-A1 | FC SILENCED ANTIBODY DRUG CONJUGATES (ADCS) AND USES THEREOF | FCGR1A, FCGR2A, FCGR3B | TRPV1 4578/4885NPY4R 4454/4885NPY5R 4027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.